Tengshengbo Pharmaceuticals and Health Element Group have reached a licensing agreement for the rights of BRII-693 in the Greater China region.

On July 4th, Tengshengbo Medicine announced that it has signed an intellectual property license and technology transfer agreement with Health Element Pharmaceuticals Group. Health Element Group will obtain exclusive license from Tengshengbo Medicine in Greater China to conduct research, development, and commercialization of BRII-693. According to the agreement, Health Element Group will be responsible for the development, regulatory approval, and commercialization of BRII-693 in Greater China. As part of the transaction consideration, Tengshengbo Medicine has received an initial payment and will receive additional development and commercialization milestone payments, as well as sales royalties based on the product's net sales. BRII-693 is a novel synthetic lipopeptide under development for the treatment of severe patients with multidrug-resistant and extensively drug-resistant gram-negative bacterial infections, especially carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa.